Here is what you need to look for: ADMA Biologics Inc. (ADMA) – Invest Chronicle

Here is what you need to look for: ADMA Biologics Inc. (ADMA)

ADMA Biologics Inc. (ADMA) is priced at $1.67 after the most recent trading session. At the very opening of the session, the stock price was $1.58 and reached a high price of $1.62, prior to closing the session it reached the value of $1.43. The stock touched a low price of $1.43.Recently in News on May 11, 2022, ADMA Biologics Announces First Quarter 2022 Financial Results and Provides Business Update. First Quarter 2022 Total Revenues Were Approximately $29.1 Million, an 81% Increase Over First Quarter 2021. You can read further details here

ADMA Biologics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $2.1550 on 04/21/22, with the lowest value was $1.2600 for the same time period, recorded on 01/13/22.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored

ADMA Biologics Inc. (ADMA) full year performance was -14.37%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, ADMA Biologics Inc. shares are logging -22.27% during the 52-week period from high price, and 65.84% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.01 and $2.15.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1928615 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the ADMA Biologics Inc. (ADMA) recorded performance in the market was 1.42%, having the revenues showcasing -14.37% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 294.55M, as it employees total of 527 workers.

Analysts verdict on ADMA Biologics Inc. (ADMA)

During the last month, 0 analysts gave the ADMA Biologics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.6410, with a change in the price was noted +0.42. In a similar fashion, ADMA Biologics Inc. posted a movement of +32.42% for the period of last 100 days, recording 2,340,390 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ADMA is recording 0.67 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.67.

ADMA Biologics Inc. (ADMA): Technical Analysis

Raw Stochastic average of ADMA Biologics Inc. in the period of last 50 days is set at 36.55%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 36.55%. In the last 20 days, the company’s Stochastic %K was 17.96% and its Stochastic %D was recorded 10.99%.

Let’s take a glance in the erstwhile performances of ADMA Biologics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 1.42%. Additionally, trading for the stock in the period of the last six months notably improved by 0.70%, alongside a downfall of -14.37% for the period of the last 12 months. The shares increased approximately by -27.78% in the 7-day charts and went up by -27.78% in the period of the last 30 days. Common stock shares were lifted by -14.37% during last recorded quarter.

Leave a Comment

Your email address will not be published.

On Key

Related Posts